Saturday 17 October 2026
Export DNTH’s income statement to Excel — free account
Dianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024. In the quarter to June 2026, revenue grew 294.3%, EPS fell 2.27% and free cash flow fell 105.4%, each against the same quarter a year earlier.
72.09
2.44
−3.27%
Follow DNTH
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | 4 | 2 |
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 0.00 | 20.88 | 116.48 | 781.65 |
Altman Z-Score |
— | — | — | — | — | — | (0.45) | 2.61 | 19.55 | 24.31 |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | 9.81 | 19.54 | 18.44 | 14.17 |
P/Operating CF |
— | — | — | — | — | — | (0.65) | (4.98) | (26.46) | (33.87) |
Beneish M-Score |
— | — | — | — | — | — | — | (4.68) | 8.16 | (4.75) |
P/B ratio |
— | — | — | — | — | — | 0.00 | 0.35 | 2.06 | 3.23 |
Price to Tangible BV |
— | — | — | — | — | — | 0.00 | 0.35 | 2.06 | 3.23 |
EV/Sales |
— | — | — | — | — | — | 0.00 | (40.59) | 72.33 | 583.07 |
EV/EBITDA |
— | — | — | — | — | — | 2.31 | 2.33 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | 2.40 | 3.11 | (5.77) | (9.20) |
EV/FCF |
— | — | — | — | — | — | 2.39 | 3.10 | (5.76) | (9.18) |
Quick Ratio |
4.69 | 12.45 | 13.68 | 10.32 | 13.02 | 16.29 | 9.86 | 18.09 | 14.96 | 13.16 |
Current Ratio |
4.71 | 12.68 | 13.95 | 10.62 | 13.26 | 16.63 | 9.97 | 18.43 | 15.22 | 13.32 |
Net Debt/EBITDA |
0.49 | 1.46 | 2.41 | 1.80 | 1.94 | 2.43 | 2.50 | 3.53 | 2.56 | 2.20 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.02 | 0.02 | 0.00 |
Operating CF/Net income |
0.67 | 0.63 | 0.73 | 0.74 | 0.85 | 0.84 | 1.02 | 0.85 | 0.92 | 0.80 |
Capex/Depreciation |
(23.17) | (5.85) | (8.75) | (1.66) | (0.20) | (0.63) | 0.30 | 0.10 | 0.02 | 0.04 |
Interest Coverage |
(56.86) | (151.39) | (24.49) | (13.38) | (20.90) | (746.92) | (21.22) | — | — | — |
| 38.18% | 139.26% | (111.28%) | (53.53%) | (52.57%) | (44.94%) | (44.39%) | (69.97%) | (32.60%) | (38.38%) | |
| (29.59%) | (107.92%) | (54.40%) | (48.16%) | (46.38%) | (40.47%) | (20.86%) | (33.18%) | (30.71%) | (35.88%) | |
ROIC |
0.00% | 0.00% | (1,217.57%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (82.43%) | (124.80%) |
Return on Tangible Assets |
(107.66%) | (70.57%) | (39.69%) | (52.72%) | (50.49%) | (40.12%) | (38.51%) | (25.92%) | (32.35%) | (42.83%) |
Average Days of Receivables |
0.00 | — | — | — | — | — | 320.69 | 61.74 | 47.24 | 9.32 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 457.83% | 1,162.10% | 1,332.88% | 7,153.14% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 105.08% | 642.57% | 400.87% | 1,686.20% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.66% | 102.62% | 206.80% | 1,119.50% |
Graham Net Nets |
— | — | — | — | — | — | 12.66 | 2.83 | 0.36 | 0.23 |
Graham Number |
— | — | — | — | — | — | 192.72 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (495.70%) | (221.20%) | (11.93%) | (9.95%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (509.45%) | (62.66%) | (10.78%) | (8.12%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.34 | 0.55 | 0.19 | 0.05 |
Operating CF per Share |
(702.04) | (191.76) | (36.44) | (24.68) | (23.32) | (17.33) | (33.26) | (7.15) | (2.35) | (3.34) |
Capex per Share |
(14.95) | (18.94) | (6.66) | (1.32) | (0.15) | (0.37) | (0.16) | (0.02) | 0.00 | (0.01) |
Free Cash Flow per Share |
(716.99) | (210.70) | (43.11) | (26.01) | (23.47) | (17.70) | (33.42) | (7.17) | (2.35) | (3.35) |
Cash per Share |
488.49 | 444.16 | 124.05 | 62.99 | 54.22 | 51.52 | 86.37 | 33.71 | 8.26 | 10.47 |
Shareholders Equity per Share |
(954.19) | (362.77) | 126.73 | 61.03 | 52.42 | 50.28 | 84.27 | 32.77 | 10.58 | 12.78 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(954.19) | (362.77) | 126.73 | 61.03 | 52.42 | 50.28 | 84.27 | 32.77 | 10.58 | 12.78 |
Free Cash Flow |
(6.67) | (24.46) | (49.55) | (60.16) | (64.42) | (60.79) | (29.21) | (36.97) | (78.28) | (129.27) |
Working Capital |
8.53 | 48.36 | 134.90 | 135.73 | 140.10 | 169.83 | 73.81 | 167.82 | 262.45 | 378.71 |
Capital Expenditures |
(0.14) | (2.20) | (7.66) | (3.06) | (0.40) | (1.26) | (0.14) | (0.11) | (0.10) | (0.21) |
Net Current Asset Value |
(9.38) | (44.08) | 133.66 | 129.52 | 133.81 | 163.43 | 72.58 | 166.92 | 259.37 | 371.92 |
EV/EBIT |
— | — | — | — | — | — | 2.35 | 2.38 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.04 | 0.02 | 0.10 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.01 | 0.19 | 0.09 | 0.19 | 0.24 | 0.27 | (3.23) | (5.77) | (28.90) | (19.37) |
Cash ROIC |
153.96% | (258.88%) | (17.19%) | (20.97%) | (22.01%) | (17.39%) | (19.58%) | (10.79%) | (12.47%) | (14.40%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 1.08 | 0.92 | 9.70 | 4.74 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | — | — | 5.94 | 3.06 | 0.64 | 0.43 |
Average Payables |
0.92 | 0.92 | 1.83 | 3.15 | 3.29 | 3.40 | 2.10 | 1.89 | 3.59 | 7.15 |
Average Assets |
32.90 | 32.90 | 105.89 | 159.41 | 161.57 | 175.78 | 136.52 | 131.26 | 276.71 | 452.47 |
Average Common Equity |
(25.50) | (25.50) | 51.77 | 143.42 | 142.55 | 158.29 | 64.15 | 62.25 | 260.67 | 422.94 |
Columns are period end dates